Showing studies related to your query4 results shown

Program Matched

Setidegrasib

Featured

Astellas Pharma Global Development, Inc.

ASP3082 / setidegrasib is Astellas’s investigational KRAS G12D-targeted protein degrader, positioned as a precision oncology asset for tumors driven by one of t…

Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma

Studies (4 shown)

NCT07409272PHASE3RECRUITING

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Sponsor · Astellas Pharma Global Development, Inc.Condition · Pancreatic Cancer, Metastatic Pancreatic CancerIntervention · Setidegrasib, OxaliplatinUpdated May 2026
NCT07566052PHASE3NOT_YET_RECRUITING

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Sponsor · Astellas Pharma Global Development, Inc.Condition · Non-small Cell Lung Cancer (NSCLC)Intervention · Setidegrasib, DocetaxelUpdated May 2026
NCT05382559PHASE1RECRUITING

A Study of ASP3082 in Adults With Advanced Solid Tumors

Sponsor · Astellas Pharma IncCondition · Solid TumorIntervention · Setidegrasib, CetuximabUpdated Apr 2026
NCT07395024PHASE1RECRUITING

A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults

Sponsor · Astellas Pharma Global Development, Inc.Condition · Healthy VolunteerIntervention · Setidegrasib, FluconazoleUpdated Mar 2026
Showing top 4 results. See all 4 results on CT.gov →